OBJECTIVE: Estrogens decrease atherosclerosis progression, mediated in part through changes in plasma lipids and lipoproteins. This study aimed to determine estrogen-induced changes in hepatic cholesterol metabolism, plasma lipoproteins, and the relationship of these changes to atherosclerosis extent. METHODS AND RESULTS: Ovariectomized monkeys (n=34) consumed atherogenic diets for 30 months which contained either no hormones (control, n=17) or conjugated equine estrogens (CEE, n=17) at a human dose equivalent of 0.625 mg/d. Hepatic cholesterol content, low-density lipoprotein (LDL) receptor expression, cholesterol 7 alpha-hydroxylase and acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity, and expression levels were determined. CEE treatment resulted in lower plasma concentrations of very-low- and intermediate- density lipoprotein cholesterol (V+IDLC; P=0.01), smaller LDL particles (P=0.002), and 50% lower hepatic cholesterol content (total, free, and esterified; P<0.05 for all). Total ACAT activity was significantly lower (P=0.01), explained primarily by reductions in the activity of ACAT2. Estrogen regulation of enzymatic activity was at the protein level as both ACAT1 and 2 protein, but not mRNA levels, were lower (P=0.02 and <0.0001, respectively). ACAT2 activity was significantly associated with hepatic total cholesterol, plasma V+IDLC cholesterol, and atherosclerosis. CONCLUSIONS: Atheroprotective effects of estrogen therapy may be related to reduced hepatic secretion of ACAT2-derived cholesteryl esters in plasma lipoproteins.
OBJECTIVE: Estrogens decrease atherosclerosis progression, mediated in part through changes in plasma lipids and lipoproteins. This study aimed to determine estrogen-induced changes in hepatic cholesterol metabolism, plasma lipoproteins, and the relationship of these changes to atherosclerosis extent. METHODS AND RESULTS: Ovariectomized monkeys (n=34) consumed atherogenic diets for 30 months which contained either no hormones (control, n=17) or conjugated equine estrogens (CEE, n=17) at a human dose equivalent of 0.625 mg/d. Hepatic cholesterol content, low-density lipoprotein (LDL) receptor expression, cholesterol 7 alpha-hydroxylase and acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity, and expression levels were determined. CEE treatment resulted in lower plasma concentrations of very-low- and intermediate- density lipoprotein cholesterol (V+IDLC; P=0.01), smaller LDL particles (P=0.002), and 50% lower hepatic cholesterol content (total, free, and esterified; P<0.05 for all). Total ACAT activity was significantly lower (P=0.01), explained primarily by reductions in the activity of ACAT2. Estrogen regulation of enzymatic activity was at the protein level as both ACAT1 and 2 protein, but not mRNA levels, were lower (P=0.02 and <0.0001, respectively). ACAT2 activity was significantly associated with hepatic total cholesterol, plasma V+IDLC cholesterol, and atherosclerosis. CONCLUSIONS: Atheroprotective effects of estrogen therapy may be related to reduced hepatic secretion of ACAT2-derived cholesteryl esters in plasma lipoproteins.
Authors: A Karjalainen; J Heikkinen; M J Savolainen; A C Bäckström; Y A Kesäniemi Journal: Arterioscler Thromb Vasc Biol Date: 2000-04 Impact factor: 8.311
Authors: H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen Journal: Ann Intern Med Date: 2001-12-04 Impact factor: 25.391
Authors: P Parini; B Angelin; A Stavréus-Evers; B Freyschuss; H Eriksson; M Rudling Journal: Arterioscler Thromb Vasc Biol Date: 2000-07 Impact factor: 8.311
Authors: Thomas A Bell; Kathryn Kelley; Martha D Wilson; Janet K Sawyer; Lawrence L Rudel Journal: Arterioscler Thromb Vasc Biol Date: 2007-04-12 Impact factor: 8.311
Authors: J Mark Brown; Thomas A Bell; Heather M Alger; Janet K Sawyer; Thomas L Smith; Kathryn Kelley; Ramesh Shah; Martha D Wilson; Matthew A Davis; Richard G Lee; Mark J Graham; Rosanne M Crooke; Lawrence L Rudel Journal: J Biol Chem Date: 2008-02-14 Impact factor: 5.157
Authors: K M Fanning; B Pfisterer; A T Davis; T D Presley; I M Williams; D H Wasserman; J M Cline; K Kavanagh Journal: Am J Physiol Regul Integr Comp Physiol Date: 2017-07-12 Impact factor: 3.619
Authors: Kylie Kavanagh; Ashley T Wylie; Kelly L Tucker; Timothy J Hamp; Raad Z Gharaibeh; Anthony A Fodor; John M Cullen Cullen Journal: Am J Clin Nutr Date: 2013-08 Impact factor: 7.045
Authors: Kylie Kavanagh; Mark A Espeland; Kim Sutton-Tyrrell; Emma Barinas-Mitchell; Samar R El Khoudary; Rachel P Wildman Journal: Obesity (Silver Spring) Date: 2013-05 Impact factor: 5.002